Portfolio

Home » Portfolio » Life Science » Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), is a specialty pharmaceutical company developing novel formulations of proven CNS agents to provide meaningful new patient benefits. Transcept priority projects include the development of products for insomnia and alcohol dependence.

Transcept Pharmaceuticals in the News

05.01.13 Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013
04.10.13 Thomas J. Dietz, Ph.D., Appointed To The Transcept Pharmaceuticals Board Of Directors
02.28.13 Transcept Pharmaceuticals to Present at Cowen and Company Health Care Conference on March 6
02.21.13 Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Financial Results and Host Conference Call on February 27, 2013
02.05.13 Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences

01.10.13

Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements for Zolpidem Based Prescription Sleep Aids Administered at Bedtime

12.21.12

Transcept Pharmaceuticals Announces that a Phase 2 Clinical Trial of TO-2061 as Adjunctive Therapy for Obsessive Compulsive Disorder Did Not Meet Primary Endpoint

11.26.12

Transcept Pharmaceuticals Announces Broadened Intermezzo® Commercialization Strategy Including Initiation of a Direct to Consumer Advertising Campaign by Purdue Pharma

11.26.12

Transcept Pharmaceuticals to Host Conference Call to Discuss Broadened Intermezzo® Commercialization Strategy and New Consumer Advertising Campaign by Purdue Pharma

11.06.12 Transcept Pharmaceuticals to Report Third Quarter 2012 Financial Results and Host Conference Call on November 12, 2012

09.12.12

Transcept Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Trial of TO-2061 Added as Adjunctive Therapy for Obsessive Compulsive Disorder